Sarepta Therapeutics (SRPT) Ticks Lower as Jefferies Sees No Change to Approvability

After surging 27% intra-day on news chief critic Dr. Farkas has left the FDA, Sarepta Therapeutics (NASDAQ: SRPT) is ticking modestly lower (1.4%) after-hours after Jefferies analysts said they see not impact on approvability of eteplirsen, citing a KOL.

"We hosted a call with an FDA regulatory expert on the departure of FDA former agent Dr. Farkas (clinical team leader for eteplirsen review) and its potential impact on the approval process for eteplirsen," analyst Gena Wang said. "Our KOL sees no changes on the probability of approval and believes longer delay suggests a tougher path to approval. We continue to see low probability of approval for eteplirsen and reiterate Underperform rating."

The analyst reiterated an Underperform rating and price target of $7.00

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• BHP makes $38.8bn bid for Anglo American; analyst thinks improved offer is needed
• WesBanco (WSBC) PT Lowered to $35 at DA Davidson